Advertisement
Letter to the Editor| Volume 102, P76-77, August 2017

Download started.

Ok

Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al.

Published:April 28, 2017DOI:https://doi.org/10.1016/j.maturitas.2017.04.019
Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al.
Previous ArticleBisphosphonates or denosumab discontinuation and risk of fractures
Next ArticleCorrigendum to “The trajectory of negative mood and depressive symptoms over two decades” [Maturitas 95 (2017) 36–41]
      We read with interest the comments by Anastasilakis et al. [
      • Anastasilakis A.D.
      • Yavropoulou M.P.
      • Makras P.
      Bisphosphonates or denosumab discontinuation and risk of fractures.
      Maturitas. 2017; (in press)
      ], regarding our recently published position statement [
      • Anagnostis P.
      • Paschou S.A.
      • Mintziori G.
      • Ceausu I.
      • Depypere H.
      • Lambrinoudaki I.
      • Mueck A.
      • Pérez-López F.R.
      • Rees M.
      • Senturk L.M.
      • Simoncini T.
      • Stevenson J.C.
      • Stute P.
      • Trémollieres F.A.
      • Goulis D.G.
      Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement.
      Maturitas. 2017; 101: 23-30
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Anastasilakis A.D.
        • Yavropoulou M.P.
        • Makras P.
        Bisphosphonates or denosumab discontinuation and risk of fractures.
        Maturitas. 2017; (in press)
        View in Article
        • Anagnostis P.
        • Paschou S.A.
        • Mintziori G.
        • Ceausu I.
        • Depypere H.
        • Lambrinoudaki I.
        • Mueck A.
        • Pérez-López F.R.
        • Rees M.
        • Senturk L.M.
        • Simoncini T.
        • Stevenson J.C.
        • Stute P.
        • Trémollieres F.A.
        • Goulis D.G.
        Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement.
        Maturitas. 2017; 101: 23-30
        View in Article
        • Black D.M.
        • Schwartz A.V.
        • Ensrud K.E.
        • et al.
        Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.; FLEX Research Group.
        JAMA. 2006; 296: 2927-2938
        View in Article
        • Black D.M.
        • Reid I.R.
        • Boonen S.
        • et al.
        The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).
        J. Bone Miner. Res. 2012; 27: 243-254
        View in Article
        • Ferrari S.
        • Libanati C.
        • Adami S.
        • Brown J.P.
        • Cosman F.
        • Czerwiński E.
        • de Gregório L.H.
        • Malouf J.
        • Reginster J.-Y.
        • Daizadeh N.S.
        • Wang A.
        • Wagman R.B.
        • Lewiecki E.M.
        Relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 8 years of denosumab treatment.
        J. Bone Miner. Res. 2015; 30 (Available at)
        https://www.asbmr.org/education/AbstractDetail?aid=11d861c9-68e4-4994-88e0-c6b94948e898
        View in Article
        • Brown J.P.
        • Roux C.
        • Törring O.
        • Ho P.R.
        • Beck Jensen J.E.
        • Gilchrist N.
        • Recknor C.
        • Austin M.
        • Wang A.
        • Grauer A.
        • Wagman R.B.
        Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial.
        J. Bone Miner. Res. 2013; 28: 746-752
        View in Article

      Article info

      Publication history

      Published online: April 28, 2017

      Identification

      DOI: https://doi.org/10.1016/j.maturitas.2017.04.019

      Copyright

      © 2017 Elsevier B.V. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      Linked Article

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX